Literature DB >> 25404362

4-1BB ligand signaling to T cells limits T cell activation.

So-Young Eun1, Seung-Woo Lee2, Yanfei Xu1, Michael Croft3.   

Abstract

4-1BB ligand (4-1BBL) and its receptor, 4-1BB, are both induced on T cells after activation, but little is known about the role of 4-1BBL. In this study we show that 4-1BBL can transmit signals that limit T cell effector activity under tolerogenic conditions. Cross-linking 4-1BBL inhibited IL-2 production in vitro, primarily with suboptimal TCR stimulation. Furthermore, naive 4-1BBL-deficient OT-II transgenic T cells displayed a greater conversion to effector T cells in vivo when responding to soluble OVA peptide in wild-type hosts, whereas development of Foxp3(+) regulatory T cells was not altered. A greater number of effector T cells also differentiated from naive wild-type OT-II T cells when transferred into 4-1BB-deficient hosts, suggesting that APC-derived 4-1BB is likely to trigger 4-1BBL. Indeed, effector T cells that could not express 4-1BBL accumulated in larger numbers in vitro when stimulated with 4-1BB-expressing mesenteric lymph node dendritic cells. 4-1BBL was expressed on T cells when Ag presentation was limiting, and 4-1BBL was aberrantly expressed at very high levels on T cells that could not express 4-1BB. Trans-ligation, Ab capture, and endocytosis experiments additionally showed that T cell-intrinsic 4-1BB regulated internalization of membrane 4-1BBL, implying that the strong induction of 4-1BB on T cells may counteract the suppressive function of 4-1BBL by limiting its availability. These data suggest that 4-1BBL expressed on T cells can restrain effector T cell development, creating a more favorable regulatory T cell to effector cell balance under tolerogenic conditions, and this may be particularly active in mucosal barrier tissues where 4-1BB-expressing regulatory dendritic cells present Ag.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404362      PMCID: PMC4272921          DOI: 10.4049/jimmunol.1401383

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response.

Authors:  Undine Lippert; Karolin Zachmann; David M Ferrari; Herbert Schwarz; Edgar Brunner; A H M Mahbub-Ul Latif; Christine Neumann; Afsaneh Soruri
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

2.  CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.

Authors:  J Langstein; J Michel; J Fritsche; M Kreutz; R Andreesen; H Schwarz
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

3.  Enhanced CD4 T cell responsiveness in the absence of 4-1BB.

Authors:  Seung-Woo Lee; Anthony T Vella; Byoung S Kwon; Michael Croft
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

4.  Enhanced osteoclastogenesis in 4-1BB-deficient mice caused by reduced interleukin-10.

Authors:  Hyun-Hee Shin; Ji-Eun Lee; Eun A Lee; Byoung Se Kwon; Hye-Seon Choi
Journal:  J Bone Miner Res       Date:  2006-12       Impact factor: 6.741

5.  CD137-induced apoptosis is independent of CD95.

Authors:  J Michel; S Pauly; J Langstein; P H Krammer; H Schwarz
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

6.  4-1BB ligand stimulation enhances myeloid dendritic cell maturation from human umbilical cord blood CD34+ progenitor cells.

Authors:  Young-June Kim; Geling Li; Hal E Broxmeyer
Journal:  J Hematother Stem Cell Res       Date:  2002-12

7.  Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages.

Authors:  Young Jun Kang; Sung Ouk Kim; Shigeki Shimada; Motoyuki Otsuka; Alim Seit-Nebi; Byoung S Kwon; Tania H Watts; Jiahuai Han
Journal:  Nat Immunol       Date:  2007-05-13       Impact factor: 25.606

8.  Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.

Authors:  Kan Saito; Naoya Ohara; Hitoshi Hotokezaka; Satoshi Fukumoto; Kenji Yuasa; Mariko Naito; Taku Fujiwara; Koji Nakayama
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

9.  A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production.

Authors:  Hyun-Hee Shin; Eun-A Lee; Soo-Jin Kim; Byoung S Kwon; Hye-Seon Choi
Journal:  FEBS Lett       Date:  2006-02-09       Impact factor: 4.124

10.  ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival.

Authors:  H Schwarz; F J Blanco; J von Kempis; J Valbracht; M Lotz
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

View more
  18 in total

1.  Lipid Metabolism in Tumor-Infiltrating T Cells.

Authors:  Shangwen He; Ting Cai; Juanjuan Yuan; Xiaojun Zheng; Wei Yang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  CD137-CRDI is not necessary in the role of contacting its natural ligand.

Authors:  Ling Yi; Zhuohong Yan; Hongyan Jia; Xiaojue Wang; Yanlin Zhao; Hongtao Zhang
Journal:  Immunol Cell Biol       Date:  2016-08-16       Impact factor: 5.126

3.  Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Authors:  Ugur Eskiocak; Wilson Guzman; Benjamin Wolf; Christine Cummings; Lauren Milling; Hsin-Jung Wu; Michael Ophir; Conner Lambden; Pearl Bakhru; Dana C Gilmore; Samantha Ottinger; Lucy Liu; William K McConaughy; Sunny Q He; Chao Wang; Cheuk Lun Leung; Jason Lajoie; William F Carson; Nora Zizlsperger; Michael M Schmidt; Ana C Anderson; Piotr Bobrowicz; Thomas J Schuetz; Robert Tighe
Journal:  JCI Insight       Date:  2020-03-12

4.  Erosion of Transplantation Tolerance After Infection.

Authors:  J S Young; M D Daniels; M L Miller; T Wang; R Zhong; D Yin; M-L Alegre; A S Chong
Journal:  Am J Transplant       Date:  2016-07-13       Impact factor: 8.086

5.  CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.

Authors:  Matthew H Forsberg; Ashley E Ciecko; Kyle J Bednar; Arata Itoh; Kritika Kachapati; William M Ridgway; Yi-Guang Chen
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

6.  Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.

Authors:  Aruna Bitra; Tzanko Doukov; Giuseppe Destito; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-12-13       Impact factor: 5.157

7.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 8.  Strategies to Address Chimeric Antigen Receptor Tonic Signaling.

Authors:  Adam Ajina; John Maher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.261

Review 9.  Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?

Authors:  Byungsuk Kwon
Journal:  Immune Netw       Date:  2015-06-25       Impact factor: 6.303

10.  Current perspectives of SA-4-1BBL in immune modulation during cancer.

Authors:  Shu-Ni Zhou; Rui-Zhi Ran; Li-Li Tan; Hao Guo
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.